However, GISTs can acquire drug-resistant secondary mutations in KIT [11–13] or activate alternative signaling pathways [14–16] to circumvent the inhibition of KIT after the initial response to imatinib, leading to tumor relapse. This evidence concerns the gene KIT and neoplasm.